UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
CURRENT REPORT
Pursuant
to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its
charter)
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
| of incorporation) | Identification No.) |
(Address of principal executive offices)
+1
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol | Name of Each Exchange on Which Registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth
company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On April 7, 2022, Enochian Biosciences Inc. (the “Company”) issued a press release to announce that Greg Duczynski was hired as the Company’s Senior Vice President for Clinical Operations. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information included in this Item 8.01 and in Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits: |
| EXHIBIT NO. | DESCRIPTION | LOCATION | |||
| 99.1 | Press Release dated April 7, 2022 | Furnished herewith |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ENOCHIAN BIOSCIENCES, INC. | ||
| By: | /s/ Mark R. Dybul | |
| Name: Mark R. Dybul Title: Chief Executive Officer | ||
Date: April 7, 2022
EXHIBIT 99.1
Enochian BioSciences
Announces Appointment of Senior Vice President for
Clinical Operations with 32 Years’ Experience at Pfizer
Los Angeles. April 7, 2022. Enochian BioSciences (NASDAQ: ENOB). Enochian BioSciences, Inc., a company focused on gene-modified cellular and immunotherapies in infectious diseases and cancer, announced today that Greg Duczynski is joining as Senior Vice President for Clinical Operations after a distinguished 32-year career with Pfizer. Since 2016, he has served as Senior Director, Clinical Development and Operations and Clinical Study Team Leader. He has been leading an international trial of gene therapy.
During his time at Pfizer, Greg took on increasing levels of leadership across a broad range of functions within the Clinical Operations space including Clinical Project Management, Study Management, Project Planning, Statistical Programming and Data Management.
“Greg’s extensive experience and outstanding leadership in clinical trials and advancing products to commercialization at the second largest pharmaceutical company in the world for more than three decades is an important and timely addition to Enochian BioSciences, as we prepare for the potential to begin several clinical studies in the near to medium term,” said Dr. Mark Dybul, the CEO of Enochian.
“I was very impressed by the science, project management and planning for clinical trials and commercialization of Enochian BioSciences,” Greg said. “It was not easy to leave a global powerhouse, but the potential for Enochian to grow with its two platform technologies and several promising pipelines for each is very compelling. I am very excited to be joining the team.”
#####